ODI PHARMA AB (6OD) - Net Assets
Based on the latest financial reports, ODI PHARMA AB (6OD) has net assets worth €2.38 Million EUR (≈ $2.78 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.30 Million ≈ $6.20 Million USD) and total liabilities (€2.93 Million ≈ $3.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See how leveraged is ODI PHARMA AB's balance sheet to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.38 Million |
| % of Total Assets | 44.81% |
| Annual Growth Rate | -28.84% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 224.98 |
ODI PHARMA AB - Net Assets Trend (2022–2026)
This chart illustrates how ODI PHARMA AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ODI PHARMA AB stock valuation.
Annual Net Assets for ODI PHARMA AB (2022–2026)
The table below shows the annual net assets of ODI PHARMA AB from 2022 to 2026. Also explore 6OD year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | €2.38 Million ≈ $2.78 Million |
+459.37% |
| 2025-06-30 | €424.64K ≈ $496.45K |
-78.78% |
| 2024-06-30 | €2.00 Million ≈ $2.34 Million |
-22.22% |
| 2023-06-30 | €2.57 Million ≈ $3.01 Million |
-72.22% |
| 2022-06-30 | €9.26 Million ≈ $10.83 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ODI PHARMA AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2026)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.38 Million | 100.00% |
| Total Equity | €2.38 Million | 100.00% |
ODI PHARMA AB Competitors by Market Cap
The table below lists competitors of ODI PHARMA AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sriwahana
JK:SWAT
|
$2.83 Million |
|
NEWLOX GOLD VENTURES
F:NGO
|
$2.83 Million |
|
Ecofin Global Utilities and Infrastructure Trust plc
LSE:EGL
|
$2.84 Million |
|
Geekco Technologies Corp
V:GKO
|
$2.84 Million |
|
Science Group plc
LSE:SAG
|
$2.82 Million |
|
Boustead Heavy Industries
KLSE:8133
|
$2.82 Million |
|
Falcon Gold Corp
V:FG
|
$2.82 Million |
|
AH-Vest Limited
JSE:AHL
|
$2.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ODI PHARMA AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 424,644 to 2,375,339, a change of 1,950,695 (459.4%).
- Net income of 1,987,659 contributed positively to equity growth.
- Other factors decreased equity by 36,964.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.99 Million | +83.68% |
| Other Changes | €-36.96K | -1.56% |
| Total Change | €- | 459.37% |
Book Value vs Market Value Analysis
This analysis compares ODI PHARMA AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.02x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.22x to 1.02x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €0.61 | €0.13 | x |
| 2023-06-30 | €0.17 | €0.13 | x |
| 2024-06-30 | €0.13 | €0.13 | x |
| 2025-06-30 | €0.02 | €0.13 | x |
| 2026-06-30 | €0.13 | €0.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ODI PHARMA AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 83.68%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.04%
- • Asset Turnover: 6.21x
- • Equity Multiplier: 2.23x
- Recent ROE (83.68%) is above the historical average (-337.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -78.16% | -2313.25% | 0.03x | 1.13x | €-8.17 Million |
| 2023 | -268.25% | -4948.58% | 0.02x | 3.18x | €-7.16 Million |
| 2024 | -28.39% | -2.55% | 1.82x | 6.11x | €-768.17K |
| 2025 | -1397.25% | -189.33% | 0.68x | 10.86x | €-5.98 Million |
| 2026 | 83.68% | 6.04% | 6.21x | 2.23x | €1.75 Million |
Industry Comparison
This section compares ODI PHARMA AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,264,401,123
- Average return on equity (ROE) among peers: -29.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ODI PHARMA AB (6OD) | €2.38 Million | -78.16% | 1.23x | $2.83 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $54.11 Billion | 6.89% | 0.98x | $1.21 Billion |
| PEPTONIC MEDICAL (28L) | $38.24 Million | -58.82% | 0.72x | $5.52 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $2.95 Billion | 12.14% | 0.85x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| HANSOH PHARMAC. HD-00001 (3KY) | $35.36 Billion | 15.71% | 0.13x | $22.06 Billion |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $4.89 Million | -63.10% | 0.49x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $170.06 Million | -9.56% | 0.06x | $123.09 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-11.72 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $20.26 Million | -37.64% | 0.19x | $6.62 Million |
About ODI PHARMA AB
ODI Pharma AB (publ), a pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. It offers dried flowers; and cosmetics products. ODI Pharma AB (publ) was founded in 2018 and is based in Stockholm, Sweden.